文献速递分子诊断临床微生物

Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV检测多中心评估

Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test.
PubMed 文献 · J Clin Microbiol · 2021-02-18

本研究在四个中心评估Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV检测对鼻咽拭子样本的临床性能。共测试319份样本,SARS-CoV-2阳性符合率为98.7%(74/75),阴性符合率为100%(91/91),其他分析物总符合率均为100%(153/153)。该检测对SARS-CoV-2、甲型/乙型流感病毒和RSV均显示高敏感性和准确性。

要点

  • SARS-CoV-2阳性符合率98.7%,阴性符合率100%。
  • 甲流、乙流和RSV分析物总符合率均为100%。
  • 该多重检测可用于呼吸道病毒季节的快速鉴别诊断。

核心结论

  • Xpert Xpress SARS-CoV-2/Flu/RSV检测对SARS-CoV-2、甲型流感病毒、乙型流感病毒和RSV均具有高敏感性和准确性。

研究设计与样本

  • 多中心评估,四个中心参与:Johns Hopkins Medical Microbiology Laboratory、Northwell Health Laboratories、NYC Public Health Laboratory、LAC+USC Medical Center。
  • 共纳入319份鼻咽拭子样本,经各中心标准-care核酸检测确定为SARS-CoV-2阳性(n=75)、甲型流感病毒阳性(n=65)、乙型流感病毒阳性(n=50)、RSV阳性(n=38)或阴性(n=91)。

主要发现

  • SARS-CoV-2靶标的总体阳性符合率为98.7%(n=74/75),阴性符合率为100%(n=91)。
  • 其他所有分析物的总符合率均为100%(n=153)。

关键数值与推荐

  • SARS-CoV-2阳性符合率98.7%(74/75),阴性符合率100%(91/91)。
  • 其他分析物(甲流、乙流、RSV)总符合率100%(153/153)。

临床怎么用

  • 该检测可用于呼吸道病毒季节快速鉴别SARS-CoV-2、甲型/乙型流感病毒和RSV感染,支持临床诊断和公共卫生监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the approach of respiratory virus season in the Northern Hemisphere, clinical microbiology and public health laboratories will need rapid diagnostic assays to distinguish severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from influenza virus and respiratory syncytial virus (RSV) infections for diagnosis and surveillance. In this study, the clinical performance of the Xpert Xpress SARS-CoV-2/Flu/RSV test (Cepheid, Sunnyvale, CA, USA) for nasopharyngeal swab specimens was evaluated in four centers: Johns Hopkins Medical Microbiology Laboratory, Northwell Health Laboratories, NYC Public Health Laboratory, and Los Angeles County/University of Southern California (LAC+USC) Medical Center. A total of 319 nasopharyngeal swab specimens, positive for SARS-CoV-2 (n = 75), influenza A virus (n = 65), influenza B virus (n = 50), or RSV (n = 38) or negative (n = 91) by the standard-of-care nucleic acid amplification tests at each site, were tested using the Cepheid panel test. The overall positive percent agreement for the SARS-CoV-2 target was 98.7% (n = 74/75), and the negative agreement was 100% (n = 91), with all other analytes showing 100% total agreement (n = 153). Standard-of-care tests to which the Cepheid panel was compared included the Cepheid Xpert Xpress SARS-CoV-2, Cepheid Xpert Xpress Flu/RSV, GenMark ePlex respiratory panel, BioFire respiratory panel 2.1 and v1.7, DiaSorin Simplexa COVID-19 Direct, and Hologic Panther Fusion SARS-CoV-2 assays. The Xpert Xpress SARS-CoV-2/Flu/RSV test showed high sensitivity and accuracy for all analytes included in the test. This test will provide a valuable clinical diagnostic and public health solution for detecting and differentiating SARS-CoV-2, influenza A and B virus, and RSV infections during the current respiratory virus season.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Mostafa HH, Carroll KC, Hicken R, et al. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test. J Clin Microbiol. 2021. PMID: 33298613. doi:10.1128/JCM.02955-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。